Related Experiment Video
Updated: Jul 1, 2025
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
Involvement of gut microbiota in multiple sclerosis-review of a new pathophysiological hypothesis and potential
Piotr Olejnik1, Kasper Buczma1, Agnieszka Cudnoch-Jędrzejewska1
1Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Abstract:
Multiple sclerosis (MS) is a chronic inflammatory disease that leads to demyelination and damage to the central nervous system. It is well known, the significance of the involvement and influence of the immune system in the development and course of MS. Nowadays, more and more studies are demonstrating that an important factor that affects the action of the immune system is the gut microbiota. Changes in the composition and interrelationships in the gut microbiota have a significant impact on the course of MS. Dysbiosis affects the disease course mainly by influencing the immune system directly but also by modifying the secreted metabolites and increasing mucosal permeability. The essential metabolites affecting the course of MS are short-chain fatty acids, which alter pro- and anti-inflammatory responses in the immune system but also increase the permeability of the intestinal wall and the blood-brain barrier. Dietary modification alone can have a significant impact on MS. Based on these interactions, new treatments for MS are being developed, including probiotics administration, supplementation of bacterial metabolites, fecal microbiota transplantation, and dietary changes. Further studies may serve to develop new drugs and therapeutic approaches for MS.
Insights
Multiple sclerosis (MS) is linked to gut microbiota changes impacting the immune system. Modulating gut bacteria and their metabolites shows promise for new MS treatments and dietary interventions.
Area of Science:
- Immunology
- Neuroscience
- Microbiology
Background:
- Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease.
- Immune system dysregulation is central to MS pathogenesis.
- The gut microbiota's role in immune function is increasingly recognized.
Purpose of the Study:
- To explore the influence of gut microbiota on the immune system in multiple sclerosis.
- To investigate how gut dysbiosis and its metabolites affect MS progression.
- To review emerging therapeutic strategies targeting the gut microbiome for MS.
Main Methods:
- Review of current scientific literature on MS, gut microbiota, and immunology.
- Analysis of mechanisms linking gut dysbiosis to immune responses in MS.
- Examination of metabolite production, such as short-chain fatty acids, and their effects.
Main Results:
- Gut dysbiosis significantly impacts MS by altering immune responses and increasing permeability.
- Short-chain fatty acids produced by gut bacteria modulate inflammation and barrier integrity.
- Dietary interventions and microbiome modulation show potential therapeutic benefits.
Conclusions:
- The gut microbiota is a critical factor in the development and progression of MS.
- Targeting the gut microbiome offers novel therapeutic avenues for MS management.
- Further research into microbiome-based therapies could lead to new drugs and treatments for MS.
